A5018378822- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Lung Cancer Diagnosis and Treatment
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Epigenetics and DNA Methylation
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Genetic factors in colorectal cancer
- Ferroptosis and cancer prognosis
- RNA modifications and cancer
- Advanced biosensing and bioanalysis techniques
- Genomic variations and chromosomal abnormalities
- Advances in Oncology and Radiotherapy
- Cancer therapeutics and mechanisms
- Virus-based gene therapy research
- Gastric Cancer Management and Outcomes
- Multiple and Secondary Primary Cancers
- Cholangiocarcinoma and Gallbladder Cancer Studies
Vanderbilt University Medical Center
2016-2025
Vanderbilt University
2014-2025
Vanderbilt-Ingram Cancer Center
2014-2025
Tennessee Oncology
2021-2025
Northwestern Memorial Hospital
2018-2024
Research for Equity And Community Health Trust
2024
Realistic Education in Action Coalition to Foster Health
2024
Breast Cancer Research Foundation
2021
Northwestern University
2016-2019
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2017-2018
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management patients with SCLC, including diagnosis, primary treatment, surveillance relapse, and subsequent treatment. This selection the journal focuses on metastatic (known as extensive-stage) which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms prolong survival most extensive-stage disease. Smoking cessation counseling intervention...
Epithelial-mesenchymal transition (EMT) is able to drive metastasis during progression of multiple cancer types, including non-small cell lung (NSCLC). As resistance immunotherapy has been associated with EMT and immune exclusion in melanoma, it important understand alterations T-cell infiltration the tumor microenvironment adenocarcinoma squamous carcinoma. We conducted an integrated analysis landscape NSCLCs through scores derived from a previously established 16 gene signature canonical...
Importance Tissue-based next-generation sequencing (NGS) of solid tumors is the criterion standard for identifying somatic mutations that can be treated with National Comprehensive Cancer Network guideline–recommended targeted therapies. Sequencing circulating tumor DNA (ctDNA) also identify tumor-derived mutations, and there increasing clinical evidence supporting ctDNA testing as a diagnostic tool. The value concurrent tissue profiling has not been formally assessed in large, multicancer...
Abstract Activating NRAS mutations are found in 15% to 20% of melanomas. Immune therapies have become a mainstay advanced melanoma treatment. We sought evaluate whether tumor genotype (e.g., mutations) correlates with benefit from immune therapy melanoma. identified 229 patients treated [IL2, ipilimumab, or anti-programmed cell death-1/ligand-1 (PD-1/PD-L1)] at three centers and compared clinical outcomes following for without mutations. Of the melanoma, 60 had mutation, 53 BRAF 116...
Tissue tumor mutational burden (TMB) has emerged as a potential biomarker predicting response to anti-programmed cell death-1 protein receptor (PD-1)/programmed ligand (PD-L1) therapy, but few studies have explored using circulating DNA (ctDNA) TMB in non-small lung cancer (NSCLC).A total of 136 patients with NSCLC ctDNA testing were retrospectively evaluated from single institution, along validation cohort second institution. was derived the number detected mutations over sequencing...
Abstract Background: Mutations in KRAS are among the most frequent oncogenic drivers with G12C mutation found up to ~13% of NSCLC. LY3537982 is an oral, highly selective, and potent inhibitor G12C, which preclinically delivers >90% sustained target occupancy. We present initial results from LOXO-RAS-20001, a phase 1 study patients (pts) G12C-mutant advanced solid tumors (NCT04956640). Methods: monotherapy dose escalation followed mTPI-2 method. Dose expansion cohorts included...
Importance Numerous studies show that early palliative care improves quality of life and other key outcomes in patients with advanced cancer their caregivers, although most lack access to this evidence-based model care. Objective To evaluate whether delivering via secure video vs in-person visits has an equivalent effect on non–small cell lung (NSCLC). Design, Setting, Participants Randomized, multisite, comparative effectiveness trial from June 14, 2018, May 4, 2023, at 22 US centers among...
Abstract Purpose: Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, SEZ6-targeted antibody conjugated to calicheamicin, was evaluated phase I study (NCT03639194) patients with relapsed/refractory SCLC. We report initial outcomes of ABBV-011 monotherapy. Patients and Methods: administered intravenously once every 3 weeks during dose escalation (0.3–2 mg/kg) expansion. SEZ6-positive tumors (≥25% tumor cells ≥1+ staining intensity...
ROS1 and RET fusions are targetable mutations that occur in a subset of patients with non-small cell lung cancer (NSCLC). have been understood to be independent oncogenic drivers which do not co-occur other common tyrosine kinase receptor except the acquired resistance setting. Here we present case patient stage IV CD-74-ROS1 fusion NSCLC discovered initially RNA next generation sequencing (NGS) who lorlatinib after 6 months on therapy through novel RUFY1-RET fusion, detected only NGS....
Abstract Purpose: RET is an emerging oncogenic target showing promise in phase I/II clinical trials. An understudied aspect of RET-driven cancers the extent to which co-occurring genomic alterations exist and how they may impact prognosis or therapeutic response. Experimental Design: Somatic activating were identified among 32,989 consecutive patients with metastatic solid tumors tested a cell-free circulating tumor DNA (cfDNA) assay. This comprehensive next-generation sequencing (NGS) assay...
BackgroundApproximately 10% of patients with SCLC develop a paraneoplastic syndrome (PNS). Neurologic PNS are thought to improve prognosis, which we hypothesized is related increased tumor-infiltrating lymphocytes and immune recognition.MethodsWe queried 2,512,042 medical records from single institution identify who have without performed manual, retrospective chart review. We then multiplexed fluorescence immunohistochemistry automated quantitative analysis (AQUA Technology) on tumors...
Primary analysis of VISION showed tepotinib had durable clinical activity in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). We present updated outcomes for clinically relevant subgroups.This phase II, open-label, multi-cohort study 500 mg (450 active moiety) METex14 NSCLC assessed efficacy and safety predefined subgroups according to age, prior therapies (chemotherapy immune checkpoint inhibitors), brain metastases. An ad hoc retrospective using Response...
Sitravatinib, a receptor tyrosine kinase inhibitor targeting TYRO3, AXL, MERTK receptors, and vascular epithelial growth factor 2, can shift the tumor microenvironment toward an immunostimulatory state. Combining sitravatinib with checkpoint inhibitors (CPIs) may augment antitumor activity.
Multiple sclerosis (MS) is a neurological disorder that affects more than million people world-wide. The aetiology of MS not known and there no medical treatment available can cure MS. Experimental autoimmune encephalomyelitis (EAE) T-cell-mediated disease model pathogenesis EAE/MS complex process involving activation immune cells, secretion inflammatory cytokines destruction myelin sheath in the central nervous system (CNS). Peroxisome proliferator-activated receptors (PPARs) are nuclear...
Provision of high-value care is a milestone in physician training. The authors evaluated the effect housestaff-led initiative on laboratory testing rates.Vanderbilt University Medical Center's Choosing Wisely steering committee, led by housestaff with faculty advisors, sought to reduce unnecessary daily basic metabolic panel (BMP) and complete blood count (CBC) inpatient general medicine surgical services. Intervention services received didactic session followed regular data feedback goal...
3002 Background: Small cell lung cancer (SCLC) has a dismal prognosis and new therapies are urgently needed. SEZ6 is transmembrane protein expressed in SCLC tumors that may be used as therapeutic target. ABBV-011 an antibody-drug conjugate (ADC) targeting with calicheamicin payload, which shown antitumor activity preclinical models of SCLC. Preliminary results from the monotherapy dose-escalation -expansion cohorts first-in-human study presented. Methods: Phase 1, open-label, multicenter...